



Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic

Cambridge, UK, 18 October 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces it has appointed Dr Richard Williams as SVP CMC and Development, as well as a strategic CDMO partner for its lead programme, CB307, a PSMA-targeted bispecific T-cell enhancer.

Richard will manage Crescendo's internal CMC activities and the strategic CDMO partner, ensuring the smooth transition of its products through development into the clinic. Richard has over 20 years' experience in the biopharmaceutical industry, in particular in CMC project management and development of monoclonal antibody-based products. Prior to joining Crescendo, Richard was VP CMC at Kymab Ltd, where he established their internal CMC development functions and managed a network of contract manufacturing organisations. Richard has also held senior positions at Crucell (Janssen vaccines), CAT/Medimmune, Acambis and Schering Plough Animal Health.

Richard received his PhD from the University of Surrey, Guildford, UK.

Phil Bland-Ward, Chief Scientific Officer of Crescendo Biologics, said:

"Richard comes with exceptional experience in CMC and development. His appointment is a significant step forwards for Crescendo and speaks to the attractiveness of our pipeline of multi-specific T-cell enhancers – all with novel modes of action.

"We look forward to working with Richard as we quickly progress towards the clinic."

Richard Williams, newly appointed SVP CMC and Development, also commented:

"I am excited to join Crescendo and to help accelerate CB307, a CD137-PSMA T-cell enhancer, and the pipeline of next generation immuno-oncology therapeutics, towards the clinic. Working alongside our newly appointed and internationally recognised CDMO, we will be able to demonstrate the enormous therapeutic potential that our versatile Humabody® products hold."

-Ends-



For more information, please contact:

Crescendo Biologics

Dr Peter Pack, CEO

+ 44 (0)1223 497140

info@crescendobiologics.com

For Media:

Instinctif Partners for Crescendo Biologics

Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell

+ 44 (0)20 7457 2020

crescendo@instinctif.com

About Crescendo Biologics

Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody[®] therapeutics in oncology with a focus on innovative targeted T-cell approaches.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell enhancer for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.

The Company's ability to develop multi-functional Humabody[®] therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody[®] V_H). These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches.

Crescendo Biologics is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody[®] drug conjugates (HDCs), the next generation of ADCs. Humabody[®]-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.crescendobiologics.com.